Read more
5:35 PM · 22 April 2021

Biogen stock fall despite strong quarterly results

-
-
Open account Download free app

Biogen (BIIB.US) stock dropped more than 2% despite stronger-than-expected quarterly figures.  During the first quarter, the biotech company earned $5.34 per share, minus some items, on $2.69 billion in sales. Earnings dropped 42% and sales declined 24% compared to previous year. Still both measures came in above market estimates. Analysts expected adjusted profit of $4.97 per share and $2.65 billion in sales. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the range of $17.00 to $18.50 per share, but maintained its revenues outlook between $10.45 billion and $10.75 billion. Stifel analysts pointed to the fact that the strong earnings were overshadowed by the uncertainty surrounding the company's Alzheimer’s drug aducanumab.

Biogen (BIIB.US) stock launched today's session with a bearish price gap, however sellers failed to break below the long term upward trendline and price managed to erase some of the losses. If buyers will manage to uphold momentum then another upward impulse towards the major resistance zone around $270 could be launched. However if sellers will manage to regain control then and break below the aforementioned upward trendline then support at $250.49 could be at risk. Source: xStation5

26 January 2026, 5:59 PM

The AI front is burning. Samsung close to a breakthrough in the memory war!

26 January 2026, 3:28 PM

US Open: Big Tech, Fed and Politics in Action. A Test Week Ahead for the Markets!

26 January 2026, 2:40 PM

Mercosur: Farmers’ fears are exaggerated, industry triumphs - facts vs. myths

26 January 2026, 1:58 PM

An Interesting Case of Nvidia in China. The Chip Paradox of the Year?

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits